Revolution Medicines (RVMD) says FDA allows expanded access for daraxonrasib in patients with previously treated metastatic pancreatic cancer

Revolution Medicines' announcement regarding the FDA's allowance for expanded access to daraxonrasib represents a significant positive development in their pipeline, particularly for patients with metastatic pancreatic cancer.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Contrary to the White House's baseless claims, there are no signs that Iran is running out of storage space, Tasnim reports

Anthropic looks to give more companies and organizations access to its powerful new Claude Mythos model, including in Japan, but faces opposition from the US, via Nikkei

Revolution Medicines (RVMD) says FDA allows expanded access for daraxonrasib in patients with previously treated metastatic pancreatic cancer

US Treasury Secretary Bessent says US has complete control of the Strait of Hormuz and blockade will continue until there is pre-February 27th Freedom of Navigation, via X in message to Iran leadership

Ares (ARES) CEO says demand has remained consistent despite recent market noise, seeing investors lean in; continue to exceed fundraising targets in most of our flagship fundraisers

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

 

Context

This could enhance their market positioning and potentially drive interest from investors and analysts, particularly if it aligns with favorable patient outcomes or further regulatory progress. Watch for any follow-up on efficacy or uptake in clinical settings, as these will be key indicators moving forward.

Related headlines

The whole workspace, free to try.

Try it free